Completed PHASE3 INTERVENTIONAL 2-arm NCT01592864

The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity

A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity

Sponsor: GlaxoSmithKline

Conditions Dentine Hypersensitivity

Interventions Sodium Monofluorophosphate Stannous Fluoride

Updated 6 times since 2017 Last updated: Feb 6, 2014 Started: Mar 31, 2012 Primary completion: May 31, 2012 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01592864, this PHASE3 trial focuses on Dentine Hypersensitivity and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Las Vegas, United States